According to the Xingqi Pharmaceutical announcement, the company received the “Drug Clinical Trial Approval Notice” for the SQ-25012 injection issued by the State Drug Administration and agreed to carry out clinical trials for the treatment of thyroid eye disease. This drug is a recombinant humanized IgG1 trispecific antibody. It is a class 1 innovative drug for therapeutic biological products. The company has completed pharmaceutical and non-clinical pharmacological toxicology studies, and the results show that it has good safety and clinical development value. As of the date of disclosure of the announcement, no drug of the same type has been approved for marketing.

According to the Xingqi Pharmaceutical announcement, the company received the “Drug Clinical Trial Approval Notice” for the SQ-25012 injection issued by the State Drug Administration and agreed to carry out clinical trials for the treatment of thyroid eye disease. This drug is a recombinant humanized IgG1 trispecific antibody. It is a class 1 innovative drug for therapeutic biological products. The company has completed pharmaceutical and non-clinical pharmacological toxicology studies, and the results show that it has good safety and clinical development value. As of the date of disclosure of the announcement, no drug of the same type has been approved for marketing.